These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 23817193)

  • 41. Comparison of the outcomes of stereotactic body radiotherapy and surgery in elderly patients with cT1-2N0M0 non-small cell lung cancer.
    Nakagawa T; Negoro Y; Matsuoka T; Okumura N; Dodo Y
    Respir Investig; 2014 Jul; 52(4):221-6. PubMed ID: 24998368
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preliminary report of late recurrences, at 5 years or more, after stereotactic body radiation therapy for non-small cell lung cancer.
    Matsuo Y; Shibuya K; Nagata Y; Norihisa Y; Narabayashi M; Sakanaka K; Ueki N; Mizowaki T; Hiraoka M
    J Thorac Oncol; 2012 Feb; 7(2):453-6. PubMed ID: 22252562
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stereotactic single-dose radiotherapy (radiosurgery) of early stage nonsmall-cell lung cancer (NSCLC).
    Hof H; Muenter M; Oetzel D; Hoess A; Debus J; Herfarth K
    Cancer; 2007 Jul; 110(1):148-55. PubMed ID: 17516437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer?
    Guckenberger M; Kestin LL; Hope AJ; Belderbos J; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Wilbert J; Xiao Y; Grills IS
    J Thorac Oncol; 2012 Mar; 7(3):542-51. PubMed ID: 22258475
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stereotactic radiotherapy (SBRT) as a sole or salvage therapy in non-small cell lung cancer patients.
    Dworzecki T; Idasiak A; Syguła D; Dworzecka U; Suwiński R
    Neoplasma; 2012; 59(1):114-20. PubMed ID: 22103905
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CyberKnife radiosurgery for stage I lung cancer: results at 36 months.
    Brown WT; Wu X; Fayad F; Fowler JF; Amendola BE; García S; Han H; de la Zerda A; Bossart E; Huang Z; Schwade JG
    Clin Lung Cancer; 2007 Sep; 8(8):488-92. PubMed ID: 17922973
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
    Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The feasibility and efficacy of stereotactic body radiotherapy for centrally-located lung tumors.
    Takahashi W; Yamashita H; Omori M; Kitaguchi M; Shibata-Kobayashi S; Sakumi A; Nakagawa K
    Anticancer Res; 2013 Nov; 33(11):4959-64. PubMed ID: 24222136
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis.
    Schanne DH; Nestle U; Allgäuer M; Andratschke N; Appold S; Dieckmann U; Ernst I; Ganswindt U; Grosu AL; Holy R; Molls M; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Guckenberger M
    Strahlenther Onkol; 2015 Feb; 191(2):125-32. PubMed ID: 25159135
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aggravation of dyspnea in stage I non-small cell lung cancer patients following stereotactic body radiotherapy: Is there a dose-volume dependency?
    Paludan M; Traberg Hansen A; Petersen J; Grau C; Høyer M
    Acta Oncol; 2006; 45(7):818-22. PubMed ID: 16982545
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer.
    Sher DJ; Wee JO; Punglia RS
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e767-74. PubMed ID: 21300476
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis.
    Mangona VS; Aneese AM; Marina O; Hymas RV; Ionascu D; Robertson JM; Gallardo LJ; Grills IS
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):124-32. PubMed ID: 25442337
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study.
    Miyakawa A; Shibamoto Y; Baba F; Manabe Y; Murai T; Sugie C; Yanagi T; Takaoka T
    Radiat Oncol; 2017 Sep; 12(1):152. PubMed ID: 28893300
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparing Outcomes of Patients With Early-Stage Non-Small-Cell Lung Cancer Treated With Stereotactic Body Radiotherapy Based on Frailty Status.
    Raghavan G; Shaverdian N; Chan S; Chu FI; Lee P
    Clin Lung Cancer; 2018 Sep; 19(5):e759-e766. PubMed ID: 29954680
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Changes in Pulmonary Function After Stereotactic Body Radiotherapy and After Surgery for Stage I and II Non-small Cell Lung Cancer, a Description of Two Cohorts.
    Alberts L; El Sharouni SY; Hofman FN; Van Putte BP; Tromp E; Van Vulpen M; Kastelijn EA; Schramel FM
    Anticancer Res; 2015 Dec; 35(12):6773-9. PubMed ID: 26637895
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer.
    Olsen JR; Robinson CG; El Naqa I; Creach KM; Drzymala RE; Bloch C; Parikh PJ; Bradley JD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e299-303. PubMed ID: 21477948
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant.
    Bradley JD; El Naqa I; Drzymala RE; Trovo M; Jones G; Denning MD
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1146-50. PubMed ID: 19800181
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stereotactic Body Radiotherapy (SBRT) with Lower Doses for Selected Patients with Stage I Non-small-cell Lung Cancer (NSCLC).
    Janssen S; Kaesmann L; Rudat V; Rades D
    Lung; 2016 Apr; 194(2):291-4. PubMed ID: 26842723
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
    Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
    Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.